Microarray analysis of potential biomarkers of brachial plexus avulsion caused neuropathic pain in male rat

Le Wang¹ and Jie Lao²,3,4*

Abstract
The present study aimed to investigate the expression of mRNA in the brachial plexus avulsion neuropathic pain model and analyze biological functions. Microarray mRNA assay and reverse transcriptase quantitative polymerase chain reaction (RT-PCR) were conducted. The whole blood was collected from two groups for Microarray mRNA analysis. The predicted mRNA targets were studied by gene ontology analysis and pathway analysis. We identified 3 targeted mRNAs, including PIK3CB, HRAS, and JUN. The results showed that PIK3CB, HRAS, and JUN gene expression was increased in the control group but decreased in the neuropathic pain group. These findings indicate that certain genes may be important biomarkers for the potential targets for the prevention and treatment of brachial plexus avulsion caused neuropathic pain.

Keywords: Neuropathic pain, Brachial plexus injury, mRNA, Animal models, Potential biomarkers

Introduction
Nerve injury-induced neuropathic pain remains an intractable disease due to a lack of satisfactory treatment [9]. In 2017, Palma Ciaramitaro et al. [1] investigate the prevalence of neuropathic pain after traumatic brachial plexus injury. Of the 107 patients enrolled, 69% had neuropathic pain. Neuropathic pain can significantly impair function, appetite, sleep, mood, and quality of life. Brachial plexus avulsion (BPA) induces a characteristic of pain are allodynia, hyperalgesia, and persistent pain, which is often difficult to cure [10]. The pain may be manifested as burning or pressure. Pain after BPA is resistant to most pain relief treatments the exact molecular mechanisms responsible for this pathology remain unknown [3]. Previous studies demonstrated that the mRNA plays a key role in the development and maintenance of neuropathic pain [11–13].

Some authors proved that c-Jun plays a vital role in the survival of ventral horn motoneurons in adult mice [4]. HRAS gene is related to neural substructure development [23]. Previous studies have shown that PIK3CB influences the early development of neuropathy in sensory neurons [2]. The spinal cord plays an important role in the process of central sensitization [14]. Furthermore, we aimed to investigate the mRNA changes of neuropathic pain caused by the brachial plexus avulsion model, thereby providing a novel insight into the mechanism of neuropathic pain.

Material and methods
Animals
This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Committee on the Ethics of Animal Experiments of the University of Fudan.

*Correspondence: laojie27@sina.com
² Department of Hand Surgery, Huashan Hospital, Fudan University, Shanghai, People’s Republic of China
Full list of author information is available at the end of the article
All surgery was performed under sodium pentobarbital anesthesia, and all efforts were made to minimize suffering. The experiments were conducted in male Sprague-Dawley rats (n = 20, age, eight weeks; weight, 200-250 g; supplied by the Department of Laboratory Animal Science, Fudan University, Shanghai, China).

**Surgery procedure**

All surgical procedures were performed after anesthesia induced by a 1% sodium pentobarbital solution (40 mg/kg body weight). Place the rat prone on a sterilized pad with the head oriented away from the surgeon and the right forepaw abducted and extended. Use the fingertips to locate the clavicle. With a scalpel, make a 1.5 cm horizontal incision in the skin under the clavicle 2 mm. Use micro-dissecting scissors to separate the skin from the superficial fascia, exposing the pectoralis major muscle.

The pectoralis major muscle was cut paralleled with the muscle fibers to expose the brachial plexus, leaving the cephalic vein intact. The subclavian vessels were located and the upper, middle, and lower trunks were dissected. In the complete brachial plexus avulsion (BPA) group (n = 20), the upper, middle, and lower trunks were grasped with forceps and hauled out from the spinal cord. The tissue layers were then brought together, and the skin was closed with 4–0 silk sutures (Ethicon), as described previously [7].

**Animal pain tests**

**Mechanical allodynia**

Mechanical allodynia was assessed by using the von Frey filaments (Stoelting, USA; bending force: 2.0, 4.0, 6.0, 8.0, 10.0, 15.0, and 26.0 g). The filaments were applied to the left forepaw. The threshold was the lowest force that evoked a withdrawal response. Each filament was applied five times. When rats showed at least two withdrawal responses to a filament, the bending force of the filament was defined as the withdrawal threshold [7].

**Cold allodynia**

Cold allodynia was assessed by an acetone spray test as described by Choi et al. [8]. 250 μl acetone was squirted onto the surface of the paw. Neuropathy rats frequently responded with a withdrawal that was exaggerated in amplitude and duration. The withdrawal responses were assessed on a scale of 3–0 points: 3 points, a vigorous response in which the rat licked the paw; 2 points, a response in which the paw has elevated the paw; 1 point, a response in which the paw had little or no weight born on it and 0 points, the paw was not moved [5].

**mRNA microarray**

The whole blood was collected from the rats. Total RNA was extracted from whole blood using a QIAamp RNA blood mini kit (Qiagen) the manufacturer’s instruction. RNA quality was checked with denaturing agarose gel (1.5%) electrophoresis and nucleic acid staining. Samples with 28S and 18S rRNA bands were resolved into two discrete bands that had no significant smearing below each band, and the 28S rRNA band intensity, which was approximately twice that of the 18S rRNA band, was used for subsequent procedures. Total RNA (1 μg) was labeled with Affymetrix® FlashTag™, Biotin HSR RNA Labeling kits (Affymetrix, Inc., Santa clara, CA, USA). Next, samples were hybridized to a Genechip Rat Gene 1.0 (Affymetrix, Inc.) at 60 rpm, at 48 °C for 16 h. Fluorescent images of microarray slides were scanned using a Genechip® Scanner 3000 7G (Affymetrix, Inc.). Microarrays were processed using an Agilent GeneArray Scanner with Affymetrix Microarray Suite version 5.0.0.032 software [5].

**Reverse transcription-quantitative polymerase chain reaction (RT-PCR) assay**

RNA was reverse transcribed into cDNA using Takara PrimeScript RT master mix (RR036A; Takara Biotechnology Co., Ltd., Dalian China). RT-qPCR was performed using an ABI StepOne Plus Real-Time PCR system (Thermo Fisher Scientific, Inc.) and SYBR Premix Ex Taq II master mix (Takara Biotechnology Co., Ltd.) according to the manufacturer’s protocol. The reaction system (10 μl) consisted of cDNA (1 μl), forward primers (10 μM; 0.2 μl), reverse primers (10 μM; 0.2 μl), ROX reference dye (0.2 μl), RNase-free water (3.4 μl), and SYBR-Green mixture (5 μl). The thermocycling conditions were as follows: Initial denaturation, 95 °C for 30 s, followed by 40 cycles of 95 °C for 5 s and 60 °C for 30 s. Rat actin was used as a housekeeping gene. The relative expression of genes was calculated using the $2^{-\Delta\Delta Ct}$ method [5].

**Bioinformatic evaluation**

GO analysis was applied to analyze the function of the expression genes according to the Gene Ontology, which is the crucial function of NCBI that can organize genes into hierarchical classification and uncover the gene network based on biological process and molecular function.
Pathway analysis was applied to find out the significant pathway of the differential genes according to KEGG, Biocarta, and Reactome. Still, we turn to Fisher’s exact test and $\chi^2$ test to select the most significant pathway, and the threshold of significance was decided by $P$-value and FDR. The enrichment $Re$ was calculated like the equation above [5].

**Statistical analysis**

The random variance model t-test was adopted to filter the differentially expressed mRNAs between the control and pain groups using GraphPad 5.0. Following the significance analysis and false discovery rate analysis, differentially expressed genes were selected according to their $P$-values. $P < 0.05$ was considered to indicate a statistically significant difference [5].

**Results**

**mRNA microarray**

Animals exhibiting significant decreases in the pain threshold (mechanical threshold decreases from 15 g pre-surgery to 8 g post-surgery and allodynia score increases from 0 pre-surgery to 2–3 post-surgery) were placed in the NP (Neuropathic Pain) group. 10 rats were doing the BPA surgery and 6 rats had neuropathic pain. There were 6 rats in the NP group. The sham-operated animals whose brachial plexus was just dissected but not used were assigned to the control group. There were 6 rats in the C group (Control group).

To functionally investigate a possible link between mRNA expression and the brachial plexus injury neuropathic pain, the differential expression of mRNA in the neuropathic pain and control group was analyzed. The whole blood was harvested from the rat after 2 weeks. The expression of 2717 mRNAs was detected between the pain and control group according to the changes: down and up. By contrast to the control group and the pain group, 1154 mRNAs exhibited decreased expression, and 1563 mRNAs exhibited increased expression. The differentially expressed mRNAs between neuropathic pain group and control group genes are shown in Table 1.

We have found 621 GO terms with the $P$-value < 0.05. The top 20 GO terms, ranked by $P$-value, were shown in Table 2. Most of the enriched terms were about inflammatory processes involved in protein modification and regulation of biological processes. The result was similar to the GO analysis.

To further investigate the functions of DEGs, we did a KEGG pathway analysis. The top 20 pathways were shown in Table 3. The KEGG pathway up regulation histogram (Fig. 1) and down regulation histogram (Fig. 2).

**PCR verification**

We aimed to explore the mechanism of neuropathic pain after brachial plexus avulsion and find nerve-related mRNAs. Therefore, we mainly focused on the differentially expressed genes (DEGs) dysregulated only in the neuropathic pain groups. Three mRNAs (Pik3cb, Hras, and Jun genes) were decreased expression in the neuropathic pain group. We chose three mRNAs (Pik3cb, Hras, and Jun genes) because it involved in neural substructure development [23].

To validate the microarray results, RT-qPCR was performed for Pik3cb, Hras, and Jun genes. It was found that the relative expression of 3 mRNA among them was significantly altered, which coincided with the results of the microarray (Fig. 3).

**Bioinformatics analysis of the diff-reg mRNA**

The Pik3cb, Hras, and Jun genes were intersection genes, which were involved in neuropathic pain according to GO and pathway analyses. The results showed that Pik3cb, Hras, and Jun gene expression was high in the control group but was low in the neuropathic pain group. The function of the Hras gene was synergetic in the aspect of axon guidance and the Neurotrophin signaling pathway. The Jun gene function was axon regeneration. The low expression of two genes in the neuropathic pain group was revealed that neuropathic pain is unfavorable for nerve regeneration.

**Discussion**

Brachial Plexus Avulsion (BPA) has been demonstrated to be a polygenic disease and its pathogenic mechanism is associated with changes in many genes. In this study, we have used microarray to identify differentially expressed genes (DEGs) and activated signaling pathways in association with BPA-induced neuropathic pain (NP) in a rat BPA model. Experiments were only conducted in male rats because our previous study used male rats [5, 7, 11]. In the next experiment, we will compare the DEGs differences between male and female rats. Theodore Price et al. demonstrated that sex differences in the mechanisms contributing to the development and/or maintenance of pain in males and females [24]. Female-predominant DEGs in sensory neurons related to inflammatory, synaptic transmission and extra cellular matrix reorganization processes; Male-selective DEGs were linked to oxidative phosphorylation and protein/molecule metabolism and production [24]. Our results have shown similar trend.

The results of GO and KEGG pathway enrichment analyses have shown similar trends, since many enriched terms or pathways were inflammatory processes and...
immune responses related [27, 28]. Up to date, many evidence suggested that both axonal regeneration and functional recovery are important contributors to neuropathic pain [25, 29]. These findings are all consistent with our present study. The KEGG analysis unraveled several signaling pathways enriched in BPA (brachial plexus avulsion) model rats. Among these pathways, phagosome, chemokine signaling, and oxidative phosphorylation pathways especially attracted our attention since they have been implicated in mediating chronic pain.

We showed that Jun, HRAS, and PIK3B were the nerve-related downregulated DEGs. Our results are consistent with that of previous studies [7]. Although the precise roles of the three marker genes in BPA-induced NP are not completely understood, our data highlighted the diagnostic and treatment potential of this disease.

We noticed that the most significantly enriched biological process of downregulated KEGG pathway was Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, etc. At this stage, we have no idea how these processes might be related with neuropathic pain. How these biological processes might be related with

Table 1  The most significant upregulated genes or downregulated genes in the neuropathic pain group

| Probe set ID | Gene symbol | Gene description                | P-value | FD |
|--------------|-------------|---------------------------------|---------|----|
| 10,937,619   | LOC685774   | Hypothetical protein            | 0.0253862 | -3.68 |
| 10,937,311   | Mir448      | microRNA                        | 0.0380793 | -3.55 |
| 10,936,853   | Midlip1     | MID1 protein                     | 0.0390031 | -3.53 |
| 10,934,445   | Ogt         | GlcNAc transferase              | 0.0395949 | -3.4  |
| 10,929,600   | Pde6d       | Phosphodiesterase 6D            | 0.0389264 | -3.32 |
| 10,929,445   | Tm4sf20     | Transmembrane                   | 0.0374806 | -3.28 |
| 10,925,373   | Ube2f       | Ubiquitin-conjugating enzyme E2F| 0.0308392 | -3.11 |
| 10,911,048   | Dapk2       | Death-associated kinase 2       | 0.0257355 | -3.11 |
| 10,908,788   | Zbtb44      | Zinc finger and BTB domain conta| 0.0406164 | -3.09 |
| 10,905,558   | Rpl26       | Ribosomal protein L26           | 0.0278983 | -2.95 |
| 10,714,907   | Ifit1       | Interferon-induced              | <1e-07   | 149.84 |
| 10,886,573   | Ifi27       | Interferon, alpha-inducible pro| <1e-07   | 40.88 |
| 10,811,177   | Ctrb1       | Chymotrysinogen B1              | <1e-07   | 24.74 |
| 10,882,317   | Isg15       | ISG 15 Ubiquitin-like modifier  | <1e-07   | 12.25 |
| 10,827,820   | RT1-T24-4   | RT1 class I, locus T24, gene 4  | <1e-07   | 9.13 |
| 10,737,262   | Sup4h1      | Suppressor of Ty4 homolog 1     | <1e-07   | 6.22 |
| 10,732,592   | Nprls       | Nitrogen permease regulator-like| <1e-07   | 4.7  |
| 10,785,144   | Xpo07       | Exportin7                       | <1e-07   | 4.19 |
| 10,749,495   | Lgals3bp    | Lectin, galactoside-binding, sol| <1e-07   | 3.72 |
| 10,704,505   | S1c1a5      | Solute carrier family 1(neutral amino acid transporter), member 5 | <1e-07   | 3.69 |
### Table 2  The top 20 most significant GO terms in the neuropathic pain group

| GO terms     | GO name                                      | Path-count | Enrichment trend |
|--------------|----------------------------------------------|------------|------------------|
| 0.009,615    | Response to virus                            | 84         | 12.30162448 up   |
| 0.045,087    | Innate immune response                       | 93         | 10.69962082 up   |
| 0.008,150    | Biological process                           | 1408       | 2.58253877 up    |
| 0.043,066    | Negative regulation of apoptotic             | 478        | 4.003318056 up   |
| 0.042,493    | Response to drug                              | 462        | 3.893443439 up   |
| 0.051,607    | Defense response to virus                    | 96         | 8.371938884 up   |
| 0.014,070    | Response to an organic cyclic compound       | 230        | 5.158362344 up   |
| 0.008,285    | Negative regulation of cell proliferation   | 308        | 4.349059161 up   |
| 0.032,355    | Response to estradiol stimulus               | 143        | 6.15591427 up    |
| 0.006,954    | Inflammatory response                        | 189        | 5.264892783 up   |
| 0.008,150    | Biological process                           | 1408       | 2.44882726 up    |
| 0.006,355    | Regulation of transcription DNA-depensent    | 681        | 2.847970082 down |
| 0.006,351    | Transcription, DNA-dependent                 | 640        | 2.862061601 down |
| 0.006,886    | Intracellular protein transport              | 167        | 4.838991083 down |
| 0.015,031    | Protein transport                            | 271        | 3.777150973 down |
| 0.006,412    | Translation                                  | 384        | 3.22634158 down  |
| 0.045,944    | Positive regulation of transcription from RNA polymerase II promoter | 715 | 2.411148564 down |
| 0.000,122    | Negative regulation of transcription from RNA polymerase II promoter | 499 | 2.699103242 down |
| 0.015,986    | ATP synthesis coupled proton transport       | 19         | 14.17739493 down |
| 0.006,302    | Double-strand brake repair                   | 48         | 7.856639688 down |

**GO gene ontology, Count enriched gene numbers in each term**

### Table 3  The top 20 most significant enriched KEGG pathways

| KEGG term | Pathname                                              | Path gene count | Enrichment trend |
|-----------|-------------------------------------------------------|-----------------|------------------|
| 04,145    | Phagosome                                             | 196             | 7.810555227 up   |
| 05,168    | Herpes simplex infection                             | 218             | 6.320100652 up   |
| 01,100    | Metabolic pathways                                   | 1272            | 2.768080422 up   |
| 04,612    | Antigen processing and presentation                   | 98              | 9.372666273 up   |
| 05,203    | Viral carcinogenesis                                  | 239             | 5.284379834 up   |
| 05,169    | Epstein-Barr virus infection                          | 232             | 5.27888016 up    |
| 04,062    | Chemokine signaling pathway                           | 180             | 5.953378762 up   |
| 04,670    | Leukocyte transendothelial migration                  | 119             | 7.07544147 up    |
| 04,516    | Viral myocarditis                                     | 110             | 7.30641939 up    |
| 04,144    | Endocytosis                                           | 236             | 4.702880923 up   |
| 00,190    | Oxidative phosphorylation                             | 162             | 7.981348255 down |
| 05,010    | Alzheimer's disease                                   | 214             | 6.545451489 down |
| 05,012    | Parkinson's disease                                   | 164             | 6.898512897 down |
| 01,100    | Metabolic pathways                                   | 1272            | 2.625938872 down |
| 05,016    | Huntington's disease                                  | 219             | 4.92009198 down  |
| 04,120    | Ubiquitin mediated proteolysis                        | 136             | 5.149730216 down |
| 04,141    | Protein processing in the endoplasmic reticulum      | 165             | 4.571135819 down |
| 04,110    | Cell cycle                                            | 126             | 5.130866735 down |
| 05,168    | Herpes simplex infection                              | 218             | 3.706933536 down |
| 05,164    | Influenza A                                           | 177             | 3.956854855 down |

**KEGG kyoto encyclopedia of genes and genomes**
neuropathic pain is unknown and still needs further investigation.

It will be very interesting to further this study into BPA patients. Microarray technology can be reliable and useful for identifying novel targets for clinical diagnostic and therapeutic approaches. This technology can be used in pancreatic cancer and renal clear cell carcinoma for diagnosis and effective therapy [15, 17].

We found that three genes expressed decreased and were related to nerve regeneration. Some authors proved that the downregulation of c-Jun gene expression is not conducive to the survival of motoneurons. HRAS might serve specific roles in the development and maintenance of nervous tissues [6]. In our study, the Metabolic signaling pathway and Phagosome signaling pathway are involved in BPA, which play a very important role in BPA-induced NP. In the peripheral nervous system, recent studies suggested that the nerve-related gene plays an important role in neuropathic pain after spinal cord injury [16]. Some authors suggested that there is a high possibility of neuropathic pain caused by nerve damage [18, 19]. The transcriptome changes play an important role in neuropathic pain [13]. So our research is meaningful and feasible. Ji-An Yang et al. [20] proved that Jun is a potential indicator for neuropathic pain. Despite increasing knowledge and ongoing study, the precise molecular mechanisms of neuropathic pain caused by brachial plexus injury remain largely unknown. Numerous studies show a significant modification of gene expression as a consequence of nerve injury. A study by Timo et al. reported that miRNAs-494, -720, -690, and -668 showed the highest signal intensities in the rat spinal cord [21]. The exosomes with Ccl3 can be efficiently detected in peripheral blood. Guan Zhang et al. [22] proved that Ccl3 can be used as a potential prognostic target for the diagnosis and treatment of spinal cord injury-induced chronic neuropathic pain in clinical applications. The microarray analysis of DEGs and pathway indifferent section by GO and KEGG suggests another method and strategy to research the target gene and pathway of nerve-related disease [22]. William Renthal et al. [25] proved that nerve injury induces distinct transcriptional responses in non-neuronal DRG cell types. The important roles of mitochondrial proteins and reactive oxygen species (ROS) metabolism, especially oxidative phosphorylation, in nerve and tissue degeneration/regeneration is highlighted by a robust literature of hundreds of papers [30]. Enhancing the mitochondrial oxidative phosphorylation process can be an effective approach for recovery from nerve damage and degeneration.

In summary, our studies indicated that Jun, HRAS, and PIK3B might serve a significant role in neuropathic pain and nerve regeneration. The three genes were downregulated in the spinal cord in NP rats after brachial plexus avulsion. Furthermore, KEGG analysis found that Metabolic pathways with significance were identified. Microarray data can provide a great source of
information in pain research [26]. These findings indicate that certain genes may be important biomarkers for the potential targets for the prevention and treatment of brachial plexus avulsion caused neuropathic pain. Several limitations should be acknowledged in our study. First, the sample size was relatively small. Besides, the results were all based on a rat model. In the future, we will perform some more in-depth studies around nerve-related genes.
**Acknowledgements**
Not applicable.

**Author contributions**
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising, or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted and agree to be accountable for all aspects of the work. All authors read and approved the final manuscript.

**Funding**
This work was supported by the Ministry of Science. The technology of China (973 Program Grant 2014CB542204).

**Availability of data and materials**
All data generated or analyzed during this study are included in this published article.

**Declarations**

**Ethics approval and consent to participate**
This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Committee on the Ethics of Animal Experiments of the University of Fudan (GB/T 35892-2018) under the section. All methods are reported following ARRIVE guidelines (https://arriveguidelines.org) for the reporting of animal experiments.

**Consent for publication**
Not applicable.

**Competing interests**
The authors declared no potential competing interest concerning the research, authorship, and/or publication of this article.

**Author details**
1 Department of Pediatric Surgery, Affiliated Ruijin Hospital, Shanghai Jiao Tong University Medical School, Shanghai, People’s Republic of China. 2 Department of Hand Surgery, Huashan Hospital, Fudan University, Shanghai, People’s Republic of China. 3 Key Laboratory of Hand Reconstruction, Ministry of Health, Shanghai, People’s Republic of China. 4 Shanghai Key Laboratory of Peripheral Nerve and Microsurgery, Shanghai, People’s Republic of China.

Received: 22 October 2021    Accepted: 18 May 2022
Published online: 26 May 2022

---

**Fig. 3** Relative expression of differentially expressed mRNA in rat whole blood in the microarray. **a** Hras were significantly down-regulated in the neuropathic pain group versus the control group after 2 weeks. **b** Jun was significantly down-regulated in the neuropathic pain group versus the control group after 2 weeks. **c** Pik3cb were significantly down-regulated in the neuropathic pain group versus the control group after 2 weeks. Data are presented as mean ± SE, *p < 0.05. NP group: neuropathic pain group.
References

1. Caramitaro P, Padia L, Devigili G, Rota E, Tamburin S, Eleopra R, Crucu G, Truin A. Neuropathic pain special interest group of the Italian neurological society. Prevalence of neuropathic pain in patients with traumatic brachial plexus injury: a multicenter prospective hospital-based study. Pain Med. 2017;18(12):2428–32. https://doi.org/10.1093/pm/ pne.360.

2. Elzinga S, Murdock BJ, Guo K, Hayes JM, Tabbey MA, Hur J, Feldman BL. Toll-like receptors and inflammation in metabolic neuropathy; a role in early versus late disease? Exp Neurol. 2019;320:112967. https://doi.org/10.1016/j.expneurol.2019.112967. (Epub 2019 May 28).

3. Fajardo J, Milthorpe BK, Santos J. Molecular mechanisms involved in neural substructure development during phosphodiesterase inhibitor treatment of mesenchymal stem cells. Int J Mol Sci. 2020;21(14):4867. https://doi.org/10.3390/ijms21144867.

4. Li YQ, Song FH, Zhong K, Yu GY, Zilundu PLM, Zhou YY, Fu R, Tang Y, Li Y, Song J, Meng C, Yang X, Liu Y, Zhou Y, Rui J, Li S, Xu C, Zhuang Y, Lao J, Zhao X. Changes in microRNA expression in the dorsal spinal cord of rats with neuropathic pain:complete brachial plexus avulsion. Neurosci Lett. 2015;589(5):52–6. https://doi.org/10.1016/j.neulet.2015.01.033. (Epub 2015 Jan 14).

5. Liu Y, Wang L, Lao J, Zhao X. Transcriptional reprogramming of distinct peripheral sensory neurons of mice. Sci Rep. 2016;6:23734. https://doi.org/10.1038/srep23734. (Epub 2016 Dec 6).

6. Malmberg K, Wang J, Xi H, Li L, Lou Z. Investigation of neuroprotective effects of erythropoietin on chronic neuropathic pain in a chronic constriction injury rat model. J Pain Res. 2020;30(13):3147–55. https://doi.org/10.2147/JPR.S285870.

7. Moore-Kurz C, Mingoli M, Zupancic S, Agostini A, Vukovic AC, Muller C, Khandekar R, Wu J. The clinical characteristics of neuropathic pain in patients with total brachial plexus avulsion: a 30-case study. Injury. 2016;47(8):1719–24. https://doi.org/10.1016/j.injury.2016.05.022. (Epub 2016 May 18).

8. Park C, Hwang J, Kim H, Park S, Koo J, Lee J. Single-cell transcriptomic analysis of somatosensory neurons uncovers temporal development of neuropathic pain. Cell Res. 2021;31(8):904–18. https://doi.org/10.1038/s12974-021-02098-y. (Epub 2021 May 28).

9. Wang Y, Ye F, Huang C, Xue F, Li Y, Gao S, Qiu Z, Li S, Chen Q, Zhou H, Song Y, He X, Yang J, Zhang Z. Bioinformatic analysis of potential biomarkers for spinal cord-injured patients with intractable neuropathic pain. Clin J Pain. 2018;34(9):825–30. https://doi.org/10.1097/AJP.0000000000000608.

10. Zhang K, Jiang X, Ji H, Li L, Lou Z. Investigation of neuroprotective effects of erythropoietin on chronic neuropathic pain in a chronic constriction injury rat model. J Pain Res. 2020;30(13):3147–55. https://doi.org/10.2147/JPR.S285870.

11. Zheng J, Wang J, Xi H, Li L, Lou Z. Decreased expression of lncRNA Malat1 in rat spinal cord contributes to neuropathic pain by increasing neuron excitability after brachial plexus avulsion. J Pain Res. 2019;12(23):1297–310. https://doi.org/10.2147/jpr.s285870. (Epub 2019 Dec 19).

12. Zhou Y, Liu P, Rui J, Zhao X. Changes in microRNA expression in the dorsal spinal cord avulsion model of neuropathic pain. Int J Mol Med. 2018;41(3):1359–67. https://doi.org/10.3892/ijmm.2017.3333. (Epub 2017 Dec 19).

13. Zhou Y, Yuan J, Zhang D, Wen S, Wang J, Li Y, Deng W. Transcriptome and molecular mechanisms and therapeutic potential. Nat Rev Neurosci. 2018;19(3):138–52. https://doi.org/10.1038/nrn.2018.2. (Epub 2018 Feb 8).

14. Zhang K, Wang J, Xi H, Li L, Lou Z. Decreased expression of lncRNA Malat1 in rat spinal cord contributes to neuropathic pain by increasing neuron excitability after brachial plexus avulsion. Neurosci Lett. 2015;589(5):52–6. https://doi.org/10.1016/j.neulet.2015.01.033. (Epub 2015 Jan 14).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more: biomedcentral.com/submissions